Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient

Imad Dibo; Satish K Pillai; Howard S Gold; Maria R Baer; Meir Wetzler; James L Slack; Peggy A Hazamy; Donna Ball; Chiu Bin Hsiao; Philip L McCarthy Jr; Brahm H Segal

doi:10.1128/JCM.42.4.1843-1845.2004

Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient

J Clin Microbiol. 2004 Apr;42(4):1843-5. doi: 10.1128/JCM.42.4.1843-1845.2004.

Authors

Imad Dibo¹, Satish K Pillai, Howard S Gold, Maria R Baer, Meir Wetzler, James L Slack, Peggy A Hazamy, Donna Ball, Chiu Bin Hsiao, Philip L McCarthy Jr, Brahm H Segal

Affiliation

¹ Department of Medicine, Roswell Park Cancer Institute, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA.

Abstract

We report a linezolid-resistant Enterococcus faecalis infection in a cord blood stem cell transplant recipient previously treated with linezolid for bloodstream infections by vancomycin-resistant enterococci. Sequencing showed a G2576U mutation in the 23S rRNA gene. Because of the important niche of linezolid in cancer treatment, linezolid-resistant E. faecalis is noteworthy.

Publication types

Case Reports

MeSH terms

Acetamides / pharmacology*
Adult
Anti-Bacterial Agents / pharmacology
Anti-Infective Agents / pharmacology*
Drug Resistance, Bacterial / genetics
Enterococcus faecalis / drug effects*
Enterococcus faecalis / isolation & purification
Female
Fetal Blood / cytology*
Gram-Positive Bacterial Infections / microbiology*
Humans
Linezolid
Microbial Sensitivity Tests
Oxazolidinones / pharmacology*
RNA, Ribosomal, 23S / genetics
Sequence Analysis, DNA
Stem Cell Transplantation / adverse effects*

Substances

Acetamides
Anti-Bacterial Agents
Anti-Infective Agents
Oxazolidinones
RNA, Ribosomal, 23S
Linezolid